Position in CADL
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$36,028,864
+$18,888,919 QoQ
Shares Held
3,497,948
0.0% QoQ
Ownership
4.57%
of shares outstanding
% of Portfolio
9.83%
of 13F equity value
Holder Rank
#5
of 138 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CADL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ACORN CAPITAL ADVISORS, LLC holds $366,458,500 across 20 Biotechnology names. CADL ranks #4 (9.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CGON |
CG Oncology, Inc.
|
1,131,500 | $80,393,075 | |
| 2 | URGN |
UroGen Pharma Ltd.
|
1,673,420 | $61,581,856 | |
| 3 | TRVI |
Trevi Therapeutics, Inc.
|
2,144,844 | $40,001,340 | |
| 4 | CADL |
Candel Therapeutics, Inc.
This page
|
3,497,948 | $36,028,864 | |
| 5 | PBYI |
Puma Biotechnology, Inc.
|
4,131,299 | $33,504,834 | |
| 6 | JBIO |
Jade Biosciences, Inc.
|
986,760 | $21,925,807 | |
| 7 | BCAX |
Bicara Therapeutics Inc.
|
643,381 | $19,101,981 | |
| 8 | KPTI |
Karyopharm Therapeutics Inc.
|
1,518,113 | $14,831,964 |
All Filings in CADL
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $36,028,864 | 3,497,948 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $17,139,945 | 3,497,948 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $14,579,921 | 2,580,517 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $13,160,636 | 2,580,517 | Shares | Sole | 2025-11-17 | |
| 2025-06-30 | $13,057,416 | 2,580,517 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $12,160,223 | 2,152,252 | Shares | Sole | 2025-05-19 | |
| 2024-12-31 | $16,836,109 | 1,939,644 | Shares | Sole | 2025-05-19 | |
| No filing history on record for this holder in this stock. | ||||||